Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

CYP2C9 polymorphism and warfarin dose requirements.

Daly AK, Day CP, Aithal GP.

Br J Clin Pharmacol. 2002 Apr;53(4):408-9. No abstract available.

2.

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR.

Pharmacogenetics. 1995 Dec;5(6):389-92. No abstract available.

PMID:
8747411
3.

Warfarin dose requirement and CYP2C9 polymorphisms.

Halkin H, Lubetsky A.

Lancet. 1999 Jun 5;353(9168):1972-3. No abstract available.

PMID:
10371596
4.

Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.

Ablin J, Cabili S, Lagziel A, Peretz H.

Isr Med Assoc J. 2002 Feb;4(2):139-41. No abstract available.

5.

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.

Redman AR.

Pharmacotherapy. 2001 Feb;21(2):235-42. Review.

PMID:
11213860
6.

Mutations of the CYP2C9 gene and the response to warfarin.

Yasar U, Oscarson M, Eliasson E, Sjöqvist F.

Surgery. 2001 Mar;129(3):384. No abstract available.

PMID:
11231472
7.

Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.

Margaglione M, Brancaccio V, Ciampa A, Di Minno G.

Thromb Haemost. 2001 Sep;86(3):938. No abstract available.

PMID:
11583336
8.

Interindividual variability in sensitivity to warfarin--Nature or nurture?

Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D.

Clin Pharmacol Ther. 2001 Aug;70(2):159-64.

PMID:
11503010
9.

CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.

Goldstein JA.

Br J Clin Pharmacol. 2002 Apr;53(4):409-10. No abstract available.

11.

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.

Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD.

J Am Coll Surg. 2002 Mar;194(3):267-73.

PMID:
11893129
12.
13.

The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.

Thijssen HH, Verkooijen IW, Frank HL.

Pharmacogenetics. 2000 Nov;10(8):757-60. No abstract available.

PMID:
11186138
14.

Genetic modulation of oral anticoagulation with warfarin.

Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G.

Thromb Haemost. 2000 Nov;84(5):775-8.

PMID:
11127854
15.

Avoiding overanticoagulation: pharmacogenomics or pragmatism?

Baglin T.

Thromb Haemost. 2001 May;85(5):945-6. No abstract available.

PMID:
11372698
16.

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.

Hermida J, Zarza J, Alberca I, Montes R, López ML, Molina E, Rocha E.

Blood. 2002 Jun 1;99(11):4237-9.

17.

Major bleeding caused by warfarin in a genetically susceptible patient.

Bloch A, Ben-Chetrit E, Muszkat M, Caraco Y.

Pharmacotherapy. 2002 Jan;22(1):97-101.

PMID:
11794436
18.

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Lee CR, Goldstein JA, Pieper JA.

Pharmacogenetics. 2002 Apr;12(3):251-63. Review. Erratum in: Pharmacogenetics 2002 Jun;12(4):343.

PMID:
11927841
19.

Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

Leung AY, Chow HC, Kwong YL, Lie AK, Fung AT, Chow WH, Yip AS, Liang R.

Blood. 2001 Oct 15;98(8):2584-7.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk